| Literature DB >> 29137162 |
Xingcui Zhang1,2, Renyong Jia3,4,5, Haoyue Shen6,7, Mingshu Wang8,9,10, Zhongqiong Yin11, Anchun Cheng12,13,14.
Abstract
Flaviviruses are enveloped, single-stranded RNA viruses that widely infect many animal species. The envelope protein, a structural protein of flavivirus, plays an important role in host cell viral infections. It is composed of three separate structural envelope domains I, II, and III (EDI, EDII, and EDIII). EDI is a structurally central domain of the envelope protein which stabilizes the overall orientation of the protein, and the glycosylation sites in EDI are related to virus production, pH sensitivity, and neuroinvasiveness. EDII plays an important role in membrane fusion because of the immunodominance of the fusion loop epitope and the envelope dimer epitope. Additionally, EDIII is the major target of neutralization antibodies. The envelope protein is an important target for research to develop vaccine candidates and antiviral therapeutics. This review summarizes the structures and functions of ED I/II/III, and provides practical applications for the three domains, with the ultimate goal of implementing strategies to utilize the envelope protein against flavivirus infections, thus achieving better diagnostics and developing potential flavivirus therapeutics and vaccines.Entities:
Keywords: envelope domains I/II/III; envelope protein; flavivirus; membrane fusion; viral infection
Mesh:
Substances:
Year: 2017 PMID: 29137162 PMCID: PMC5707545 DOI: 10.3390/v9110338
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1Flavivirus genome structure and virion. (a) The flavivirus genome consists only of an open reading frame (ORF) flanked by 5’ and 3’ untranslated regions (UTRs). The 5’UTR contains a type I cap structure (m7 GpppAm), and the 3’UTR lacks a polyadenylated (polyA) tail [25,26]. The polyprotein encoded by the ORF is processed into three structural proteins (C, prM, and E) and at least seven non-structural proteins (NS1, NS2A/B, NS3, NS4A/B, and NS5) by viral (NS2B-NS3) or host cellular proteases (host signal peptidase and host furin); (b) the C protein is responsible for coating the viral nucleic acid, and the E protein forms various symmetric structures.
Figure 2E protein structure. The E protein contains three distinct domains (EDI, purple; EDII, orange; and EDIII, green) and helix-transmembrane domains (TMDs, brown), which are linked by the stem region (grey).
Figure 3Conformational changes in the E protein during the fusion process (a) and flavivirus infection of a host cell (b). (a) The E protein undergoes conformational changes during fusion [35]. 1. In the neutral environment, the E protein monomers dimerize with each other and are anchored via the transmembrane domain; 2. The EDII fusion loop (FL, red) is exposed to the extracellular environment under low pH conditions. The E protein undergoes irreversible conformational changes and forms a hairpin-like structure, while the FL adsorbs the host cell membrane; 3. The E protein changes from a dimer to a trimer; 4. The viral and host cell membranes fuse; 5. Post-fusion formation. (b) viral infection of host cells is mediated by receptor-mediated endocytosis. The E protein is responsible for viral attachment, membrane fusion, and virion assembly; 1. When the virus enters the host cells, the E protein interacts with cellular receptors, such as lipoprotein receptor-related protein 1 (LRP1), heparan sulfate, and ribosomal protein SA (RPSA). Low pH conditions trigger the viral envelope to fuse with the endosomes; 2. Release of viral genome RNA; 3/4. The virus replicates and assembles by budding into the endoplasmic reticulum (ER) in an immature non-infectious formation; 5. The progeny viruses mature in the Golgi complex; 6. The progeny viruses are then transported to the cell surface for release by exocytosis.
E protein applications.
| Structures | Viruses | Strains | Gen Bank Accession Numbers | Application Types | References |
|---|---|---|---|---|---|
| EDIII | YFV | 17D strain | JX949181.1 | vaccine | [ |
| JEV | vaccine | [ | |||
| TBEV | vaccine | [ | |||
| TMUV | FX2010 | ELISA | [ | ||
| WNV | therapeutic | [ | |||
| E and EDIII | NY99-382 | AF196835 | vaccine | [ | |
| E | mAb | [ | |||
| New York 1999 strain | FJ151394 | diagnostic reagent | [ | ||
| EDIII | DENV | B5/ H241 | AF289029/U18433 | neutralizing epitopes | [ |
| Hawaii/New Guinea-C/Guanxi-80-2/H241 | vaccine | [ | |||
| EDI/EDII hinge | rDENV-4 | 1683917 | vaccine | [ | |
| E | DENV-1 WestPac74 | mAb | [ | ||
| DENV-2 S-16803 | |||||
| DENV-3 CH-53489 | |||||
| DENV-4 TVP-376 | |||||
| ZIKV H/PF/2013 | |||||
| ZIKV PRVABC59 | |||||
| ZIKV | H/PF/2013 | KJ776791.2 | peptide drugs | [ | |
| 50 strains | peptide vaccine | [ | |||
| 5IRE | diagnostic sites | [ |
E: Envelope, EDI/II/III: Envelope Domain I/II/III, YFV: Yellow Fever Virus, JEV: Japanese Encephalitis Virus, TBEV: Tick Borne Encephalitis Virus, TMUV: Tembusu Virus, DENV: Dengue Virus, ZIKV: Zika Virus, mAb: Monoclonal antibody, ELISA: Enzyme-linked immunosorbent assay.